<table
    cellpadding="0"
    cellspacing="0"
    width="100%"
    role="presentation"
    style="background-color: transparent; min-width: 100%"
    class="stylingblock-content-wrapper"
>
    <tr>
        <td style="padding: 10px 20px" class="stylingblock-content-wrapper camarker-inner">
            <span
                style="
                    font-family: arial, helvetica, sans-serif;
                    font-size: 16px;
                    line-height: 22px;
                    color: #333;
                "
                ><b>Advanced Treatments Now Available</b></span
            >
            <ul>
                <li>
                    <span
                        style="
                            font-family: arial, helvetica, sans-serif;
                            font-size: 16px;
                            line-height: 22px;
                            color: #333;
                        "
                        >Chimeric antigen receptor (CAR) T-cell therapy is now available at CTCA
                        Chicago.</span
                    >
                </li>
                <li>
                    <span
                        style="
                            font-family: arial, helvetica, sans-serif;
                            font-size: 16px;
                            line-height: 22px;
                            color: #333;
                        "
                        >CTCA Phoenix now offers a minimally invasive robotic-assisted bronchoscopy
                        procedures with the Ion Endoluminal System.</span
                    >
                </li>
                <li>
                    <span
                        style="
                            font-family: arial, helvetica, sans-serif;
                            font-size: 16px;
                            line-height: 22px;
                            color: #333;
                        "
                        >Both CTCA Atlanta and Chicago are now sites of care for
                        Pluvicto<sup>&reg;</sup>, a radiopharmaceutical approved by the FDA as the
                        first targeted radioligand therapy for treatment of progressive,
                        PSMA-positive metastatic prostate cancer.</span
                    >
                </li>
            </ul>
        </td>
    </tr>
</table>
